NMRA-898 — Topline data
H2 2026
The Company expects to report data from the study in the second half of 2026.Source filing
NMRA biotech catalysts & pipeline
NEUMORA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
NMRA-215 — Initial data
Late 2026
Initiate clinical program with NMRA-215 in monotherapy and combination settings in 1H 2026 and deliver proof of concept weight loss data around the end of 2026Source filing
NMRA-215 — IND submission
Q4 2026
The Company expects to submit an IND in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.Source filing
NMRA-511 — Interim data
Q4 2026
Neumora plans to report data from a MAD expansion cohort evaluating higher doses of NMRA-511 in healthy elderly participants in the fourth quarter of 2026 and to initiate a Phase 2 study with NMRA-511 in Alzheimer's disease agitation by the end of 2026.Source filing